A detailed history of Envestnet Asset Management Inc transactions in Acadia Pharmaceuticals Inc stock. As of the latest transaction made, Envestnet Asset Management Inc holds 107,543 shares of ACAD stock, worth $1.59 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
107,543
Previous 105,579 1.86%
Holding current value
$1.59 Million
Previous $1.95 Million 10.5%
% of portfolio
0.0%
Previous 0.0%

Shares

28 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 08, 2024

BUY
$14.62 - $18.42 $28,713 - $36,176
1,964 Added 1.86%
107,543 $1.75 Million
Q1 2024

May 13, 2024

SELL
$17.79 - $30.86 $806,829 - $1.4 Million
-45,353 Reduced 30.05%
105,579 $1.95 Million
Q4 2023

Feb 13, 2024

SELL
$20.78 - $31.77 $433,948 - $663,452
-20,883 Reduced 12.15%
150,932 $4.73 Million
Q3 2023

Nov 13, 2023

BUY
$20.84 - $33.47 $1.65 Million - $2.65 Million
79,298 Added 85.71%
171,815 $3.58 Million
Q2 2023

Aug 04, 2023

BUY
$17.8 - $25.65 $495,213 - $713,608
27,821 Added 43.0%
92,517 $2.22 Million
Q1 2023

May 11, 2023

BUY
$16.32 - $20.92 $166,561 - $213,509
10,206 Added 18.73%
64,696 $1.22 Million
Q4 2022

Feb 07, 2023

SELL
$14.2 - $18.63 $59,810 - $78,469
-4,212 Reduced 7.18%
54,490 $867,000
Q3 2022

Nov 10, 2022

SELL
$14.11 - $18.27 $64,172 - $83,091
-4,548 Reduced 7.19%
58,702 $960,000
Q2 2022

Aug 03, 2022

SELL
$13.01 - $27.22 $103,247 - $216,017
-7,936 Reduced 11.15%
63,250 $891,000
Q1 2022

May 04, 2022

SELL
$20.94 - $27.5 $134,874 - $177,127
-6,441 Reduced 8.3%
71,186 $1.72 Million
Q4 2021

Feb 04, 2022

SELL
$16.79 - $27.09 $417,668 - $673,890
-24,876 Reduced 24.27%
77,627 $1.81 Million
Q3 2021

Oct 07, 2021

SELL
$15.78 - $24.77 $37,714 - $59,200
-2,390 Reduced 2.28%
102,503 $1.7 Million
Q2 2021

Aug 04, 2021

BUY
$19.4 - $27.42 $68,152 - $96,326
3,513 Added 3.47%
104,893 $2.56 Million
Q1 2021

May 04, 2021

BUY
$25.02 - $54.99 $1.99 Million - $4.37 Million
79,483 Added 362.99%
101,380 $2.62 Million
Q4 2020

Feb 02, 2021

BUY
$41.04 - $56.79 $133,380 - $184,567
3,250 Added 17.43%
21,897 $1.17 Million
Q3 2020

Oct 09, 2020

BUY
$36.42 - $57.0 $97,714 - $152,931
2,683 Added 16.81%
18,647 $769,000
Q2 2020

Jul 08, 2020

BUY
$39.26 - $52.73 $4,711 - $6,327
120 Added 0.76%
15,964 $774,000
Q1 2020

Apr 23, 2020

BUY
$31.65 - $46.87 $73,269 - $108,504
2,315 Added 17.11%
15,844 $669,000
Q4 2019

Feb 11, 2020

BUY
$36.21 - $51.4 $104,827 - $148,803
2,895 Added 27.22%
13,529 $579,000
Q3 2019

Oct 17, 2019

BUY
$22.22 - $44.01 $236,287 - $468,002
10,634 New
10,634 $383,000
Q1 2019

May 10, 2019

SELL
$16.17 - $27.38 $167,505 - $283,629
-10,359 Closed
0 $0
Q4 2018

Feb 13, 2019

BUY
$14.32 - $22.92 $148,340 - $237,428
10,359 New
10,359 $168,000
Q3 2018

Nov 14, 2018

SELL
$13.03 - $21.81 $8,065 - $13,500
-619 Closed
0 $0
Q2 2018

Aug 10, 2018

BUY
$15.07 - $22.34 $1,311 - $1,943
87 Added 16.35%
619 $9,000
Q1 2018

May 09, 2018

BUY
$22.47 - $32.33 $4,808 - $6,918
214 Added 67.3%
532 $12,000
Q4 2017

Feb 20, 2018

SELL
$26.84 - $39.14 $3,838 - $5,597
-143 Reduced 31.02%
318 $10,000
Q3 2017

Nov 13, 2017

SELL
$29.49 - $38.37 $50,988 - $66,341
-1,729 Reduced 78.95%
461 $17,000
Q2 2017

Aug 14, 2017

BUY
N/A
2,190
2,190 $61,000

Others Institutions Holding ACAD

About ACADIA PHARMACEUTICALS INC


  • Ticker ACAD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 161,843,008
  • Market Cap $2.39B
  • Description
  • ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's p...
More about ACAD
Track This Portfolio

Track Envestnet Asset Management Inc Portfolio

Follow Envestnet Asset Management Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Envestnet Asset Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Envestnet Asset Management Inc with notifications on news.